Table 1.
Case reports (CR) presenting locally advanced (laBSC) and metastatic BSC (mBSC) treated with vismodegib and sonidegib.
| Study | N° of CR | Skin Neoplasm |
Treatment | Duration of Treatment (Months/Cycles) |
Time to Complete Response (Months) |
Durability of Response |
Progression |
|---|---|---|---|---|---|---|---|
| McGrane et al. Clin. Exp. Dermatol. 2017 [68] | 1 | mBSC | Vismodegib 150 mg day | 28 months | 3 | Complete response on primary BSC, partial response on metastasis | No |
| Sahuquillo-Torralba et al. Indian J. Dermatol. Venereol. Leprol. 2019 [69] | 1 | laBSC | Vismodegib 150 mg day | 7 months | 7 | 9 months after discontinuation of therapy | No |
| Apalla et al. Eur Dermatol. 2019 [70] | 2 | laBSC | Vismodegib 150 mg day | 6 months | 6 | 12 and 18 months after discontinuation of therapy | No |
| Pirruccello et al. BMJ Case Rep. 2023 [71] | 1 | laBSC | Vismodegib 150 mg day + Cemiplimab 350 mg every 3 weeks | 31 cycles of Cemiplimab |
21 | / | No |
| Toffoli et al. Dermatol. Ther. 2022. Jun, 35(6), e15436. [76] | 2 | laBSC | Sonidegib 200 mg day | On course | 6 | Therapy will be continued until disease progression or unacceptable toxicity | No |
| Dika et al. Exp Dermatol. 2023. Jul 11. [77] | 1 | laBSC | Sonidegib 200 mg day + surgery |
8 months of Sonidegib | 8 | Complete remission after 6 months | No |